Medical device and MedTech insights, news, tips and more

The Defeat of Breast Cancer Will Mark the Beginning of the End for Cancer

December 30, 2016

cancer

cancerIf the war on cancer is ever decisively and finally won, chances are good the world will look back and see that the first major turning point was the eradication of breast cancer. And this initial victory will be remembered as a smart place to have started.

For, circa 2016-17, the fight against breast cancer has the best-secured screening beachhead to build on.

It’s the struggle with the most ready, willing and able spies behind enemy lines. (I’m thinking not only of researchers and study subjects but also cancer survivors.)

And it’s one of the clashes for which technology has already rewritten the rules of engagement. Think about how fast imaging-based diagnostics have sharpened their aim—how quickly, in retrospect, the field advanced from analog film to digital 2D to digital 3D.

Also think about this: Lost in 2016’s misplaced angst over machine learning is that, by tapping computer-aided detection (CAD), mammography has been amassing experience with the technology for years.

AI is coming to all of radiology. It will build on what’s been learned from CAD in mammography. It will put an ever-sharper second set of eyes on diagnostic images, assisting rather than displacing radiologists. It will help cancer doctors heal cancer patients.

There’s still a lot of ground to take in the battle over breast cancer, of course.

By the time the ball drops in Times Square, almost a quarter-million new cases of invasive breast cancer will have been diagnosed over the prior 12 months. The disease will have taken the lives of more than 40,000 women.

Read Full Article – Source: The defeat of breast cancer will mark the beginning of the end for cancer, period | Health Imaging

Author – Dave Pearson

Photo Credit – Torin Halsey/Wichita Falls Times Record News, via Associated Press

More insights

November 11, 2024
What is the Difference Between MedTech and TechMed?  
Learn More
March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.